BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A validation study

Amber Louw, Vasiliki Panou, Weronika Maria Szejniuk, Christos Meristoudis, Siaw Ming Chai, Chris van Vliet, Y. C. Gary Lee, Ian M. Dick, Tina Firth, Louise Andersen Lynggaard, Azadeh Birbaneh Asghari, Mogens Vyberg, Johnni Hansen, Jenette Creaney*, Oluf Dimitri Røe

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

Original languageEnglish
JournalJournal of Thoracic Oncology
ISSN1556-0864
DOIs
Publication statusE-pub ahead of print - 27 Apr 2022

Bibliographical note

Copyright © 2022 International Association for the Study of Lung Cancer. All rights reserved.

Keywords

  • BAP1
  • Chemotherapy
  • Pemetrexed
  • Pleural mesothelioma
  • Predictive biomarkers

Fingerprint

Dive into the research topics of 'BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A validation study'. Together they form a unique fingerprint.

Cite this